Patents Assigned to Nucitec S.A. de C.V.
-
Publication number: 20170332690Abstract: The present invention is directed to an infant formula specially designed to reduce episodes of regurgitation, colic and constipation that occur in infants fed on infant formula. The composition represents a needed improvement to the art because it contains in a single composition substances that simultaneously addresses these three problems.Type: ApplicationFiled: March 6, 2017Publication date: November 23, 2017Applicant: Nucitec S.A. de C.V.Inventors: Jorge Luis ROSADO LORIA, Miguel Angel DUARTE-VÁZQUEZ
-
Patent number: 9591872Abstract: The present invention is directed to an infant formula specially designed to reduce episodes of regurgitation, colic and constipation that occur in infants fed on infant formula. The composition represents a needed improvement to the art because it contains in a single composition substances that simultaneously addresses these three problems.Type: GrantFiled: July 26, 2012Date of Patent: March 14, 2017Assignee: Nucitec S.A. de C.V.Inventors: Jorge Luis Rosado Loria, Miguel Angel Duarte-Vázquez
-
Patent number: 9492466Abstract: The present disclosure provides methods of treating, ameliorating, or preventing immune disorders, allergic disorders, or inflammatory disorders, or combinations thereof, or providing hepatoprotection in subject. In one aspect, the method comprises administering to a subject a therapeutically effective amount of a ?-hydroxy-?-aminophosphonate or ?-amino-?-aminophosphonate.Type: GrantFiled: March 14, 2013Date of Patent: November 15, 2016Assignee: Nucitec S.A. de C.V.Inventors: Ricardo Abraham De La Cruz Cordero, Jorge Luis Rosado Loria, Miguel Angel Duarte Vazquez, José Mario Ordóñez Palacios, Jorge Alberto Reyes Esparza, Maria de Lourdes Rodriguez Fragoso
-
Publication number: 20150245644Abstract: The present disclosure is related to the obtaining of a nutritional formula for the feeding of preterm born infants. The formula comprises a mixture of casein; whey milk protein; alphalactalbumin; beta casein A2 protein, lactose; palmitic acid in beta position; non digestible oligosaccharides; long chain polyunsaturated fatty acids (LC PUFAS); nucleotides; vitamins and minerals; inositol, choline, taurine and carnitine in concentrations sufficient enough to satisfy nutritional requirements of premature children, besides being better-tolerated.Type: ApplicationFiled: May 2, 2013Publication date: September 3, 2015Applicant: NUCITEC, S.A. DE C.V.Inventors: Jorge Luis Rosado Loria, Miguel Angel Duarte Vázquez
-
Publication number: 20150237902Abstract: An infant formula specially designed for covering nutrition necessities of infants between 0 and 36 months of life is described, which reduces the intolerance problems related to the consumption of infant formulas currently found in the art.Type: ApplicationFiled: May 2, 2013Publication date: August 27, 2015Applicant: Nucitec, S.A. DE C.V.Inventors: Jorge Luis Rosado Loria, Miguel Angel Duarte Vázquez
-
Patent number: 9056134Abstract: The present invention is in the fields of medicine, pharmaceuticals, nutraceuticals, endocrinology and cardiology. The invention provides compositions comprising a statin, an inhibitor of the angiotensin converting enzyme, an antiplatelet compound and an anti-hyperglycemic compound for use in the treatment and/or prevention of cardiometabolic risk factors of Metabolic Syndrome and treatment and/or prevention of Metabolic Syndrome. The present invention provides for the use of such compositions in the manufacture of products for treatment and/or prevention of Metabolic Syndrome. The biguanide metformin of the composition could be present in extended release form allowing its use together with the other drugs in a single dosage form at low dose. This combination of drugs in a single daily dosage greatly improves compliance and adherence to treatment which is a critical factor for treating patients with Metabolic Syndrome.Type: GrantFiled: July 21, 2011Date of Patent: June 16, 2015Assignee: NUCITEC S.A. DE C.V.Inventors: Miguel Angel Duarte-Vazquez, Sandra Garcia Padilla, Jorge Luis Rosado
-
Patent number: 8790714Abstract: The present invention is in the fields of medicine, pharmaceuticals, neutraceuticals and rheumatology. In one aspect, the invention provides pharmaceutical compositions for the treatment and/or prevention of osteoarthritis in mammals, particularly humans, comprising sodium bicarbonate and calcium gluconate, and optionally comprising one or more additional components. The invention also provides methods of treating or preventing osteoarthritis by administering to a mammal, preferably via intraarticular injection, one or more compositions of the invention.Type: GrantFiled: August 4, 2008Date of Patent: July 29, 2014Assignee: Nucitec, S.A. de C.V.Inventors: Ricardo Amador, Jorge L. Rosado, Sandra García-Padilla, Miguel Ángel Duarte-Vázquez
-
Patent number: 8779006Abstract: The present invention is in the fields of medicine, pharmaceuticals, neutraceuticals and rheumatology. The invention provides pharmaceutical compositions for the treatment and/or prevention of osteoarthritis in mammals, particularly humans, comprising sodium bicarbonate and calcium gluconate, and optionally comprising one or more additional components. The invention also provides methods of treating or preventing osteoarthritis by administering to a mammal, preferably via intraarticular injection, one or more compositions of the invention.Type: GrantFiled: September 16, 2011Date of Patent: July 15, 2014Assignee: Nucitec S.A. de C.V.Inventors: Ricardo Amador, Jorge L. Rosado, Sandra García-Padilla, Miguel Ángel Duarte-Vázquez
-
Patent number: 8536362Abstract: The present invention provides ?-hydroxy-?-aminophosphonates, ?-amino-?-aminophosphonates, and analogs thereof that inhibit carnitine acyltransferases. The invention also provides compositions comprising these ?-hydroxy-?-aminophosphonates, ?-amino-?-aminophosphonates, and analogs, and methods of the use of such compounds and compositions in the treatment, amelioration or prevention of pathological conditions, diseases or disorders that are linked with fatty acid metabolism, such as non-insulin dependent diabetes or obesity. The invention also provides processes for the preparation of such compounds and compositions.Type: GrantFiled: March 22, 2012Date of Patent: September 17, 2013Assignee: Nucitec S.A. de C.V.Inventors: Ricardo Abraham De La Cruz Cordero, Miguel Ångel Duarte Vázquez, Jorge Luis Rosado Loria
-
Publication number: 20130189398Abstract: The present invention is directed to an infant formula specially designed to reduce episodes of regurgitation, colic and constipation that occur in infants fed on infant formula. The composition represents a needed improvement to the art because it contains in a single composition substances that simultaneously addresses these three problems.Type: ApplicationFiled: July 26, 2012Publication date: July 25, 2013Applicant: Nucitec S.A. de C.V.Inventors: Jorge Luis ROSADO LORIA, Miguel Angel Duarte-Vázquez
-
Publication number: 20130079308Abstract: The present invention provides ?-hydroxy-?-aminophosphonates, ?-amino-?-aminophosphonates, and analogs thereof that inhibit carnitine acyltransferases. The invention also provides compositions comprising these ?-hydroxy-?-aminophosphonates, ?-amino-?-aminophosphonates, and analogs, and methods of the use of such compounds and compositions in the treatment, amelioration or prevention of pathological conditions, diseases or disorders that are linked with fatty acid metabolism, such as non-insulin dependent diabetes or obesity. The invention also provides processes for the preparation of such compounds and compositions.Type: ApplicationFiled: March 22, 2012Publication date: March 28, 2013Applicant: Nucitec S.A. de C.V.Inventors: Ricardo Abraham De La Cruz Cordero, Miguel Ångel Duarte Vázquez, Jorge Luis Rosado Loria
-
Patent number: 8178515Abstract: The present invention provides ?-hydroxy-?-aminophosphonates, ?-amino-?-aminophosphonates, and analogs thereof that inhibit carnitine acyltransferases. The invention also provides compositions comprising these ?-hydroxy-?-aminophosphonates, ?-amino-?-aminophosphonates, and analogs, and methods of the use of such compounds and compositions in the treatment, amelioration or prevention of pathological conditions, diseases or disorders that are linked with fatty acid metabolism, such as non-insulin dependent diabetes or obesity. The invention also provides processes for the preparation of such compounds and compositions.Type: GrantFiled: October 8, 2009Date of Patent: May 15, 2012Assignee: Nucitec S.A. de C.V.Inventors: Ricardo Abraham De La Cruz Cordero, Miguel Angel Duarte-Vazquez, Jorge Luis Rosado Loria
-
Publication number: 20120021048Abstract: The present invention is in the fields of medicine, pharmaceuticals, nutraceuticals and cardiology. The invention provides compositions comprising a statin, an inhibitor of the angiotensin converting enzyme, an antiplatelet compound and an antioxidant compound for the treatment and/or prevention of cardiovascular disease.Type: ApplicationFiled: July 21, 2011Publication date: January 26, 2012Applicant: Nucitec S.A. de C.V.Inventors: Miguel Angel Duarte-Vazquez, Sandra Garcia Padilla, Jorge L. Rosado
-
Publication number: 20120021049Abstract: The present invention is in the fields of medicine, pharmaceuticals, nutraceuticals, endocrinology and cardiology. The invention provides compositions comprising a statin, an inhibitor of the angiotensin converting enzyme, an antiplatelet compound and an anti-hyperglycemic compound for use in the treatment and/or prevention of cardiometabolic risk factors of Metabolic Syndrome and treatment and/or prevention of Metabolic Syndrome. The present invention provides for the use of such compositions in the manufacture of products for treatment and/or prevention of Metabolic Syndrome. The biguanide metformin of the composition could be present in extended release form allowing its use together with the other drugs in a single dosage form at low dose. This combination of drugs in a single daily dosage greatly improves compliance and adherence to treatment which is a critical factor for treating patients with Metabolic Syndrome.Type: ApplicationFiled: July 21, 2011Publication date: January 26, 2012Applicant: Nucitec S.A. de C.V.Inventors: Miguel Angel Duarte-Vázquez, Sandra Garcia Padilla, Jorge Luis Rosado
-
Publication number: 20100234442Abstract: The present invention is in the fields of medicine, pharmaceuticals, neutraceuticals and cardiology. In one aspect, the invention provides compositions comprising enalapril and simvastatin for use in methods for the treatment and/or prevention of cardiovascular disease, and to the use of such compositions in the manufacture of products for such treatment and/or prevention. In another aspect, the invention provides methods for the treatment and/or prevention of cardiovascular disease using compositions comprising enalapril, simvastatin and acetylsalicylic acid. The compositions and methods of the invention are useful in the treatment and prevention of cardiovascular disease in a variety of animals, particularly humans.Type: ApplicationFiled: March 12, 2010Publication date: September 16, 2010Applicant: Nucitec S.A. de C.V.Inventors: Miguel Angel Duarte-Vazquez, Jorge Luis Rosado Loria
-
Publication number: 20100087400Abstract: The present invention provides ?-hydroxy-?-aminophosphonates, ?-amino-?-aminophosphonates, and analogs thereof that inhibit carnitine acyltransferases. The invention also provides compositions comprising these ?-hydroxy-?-aminophosphonates, ?-amino-?-aminophosphonates, and analogs, and methods of the use of such compounds and compositions in the treatment, amelioration or prevention of pathological conditions, diseases or disorders that are linked with fatty acid metabolism, such as non-insulin dependent diabetes or obesity. The invention also provides processes for the preparation of such compounds and compositions.Type: ApplicationFiled: October 8, 2009Publication date: April 8, 2010Applicant: Nucitec S.A. de C.V.Inventors: Ricardo Abraham De La Cruz Cordero, Miguel Angel Duarte Vázquez, Jorge Luis Rosado Loria